TY  - JOUR
A1  - Leuw, Philipp de
A1  - Arendt, Christophe
A1  - Haberl, Annette E.
A1  - Froadinadl, Daniel
A1  - Kann, Gerrit
A1  - Wolf, Timo
A1  - Stephan, Christoph
A1  - Schüttfort, Gundolf
A1  - Vasquez, Moises
A1  - Arcari, Luca
A1  - Zhou, Hui
A1  - Zainal, Hafisyatul
A1  - Gawor, Monika
A1  - Vidalakis, Eleftherios
A1  - Kolentinis, Michael
A1  - Albrecht, Moritz Hans Ernst
A1  - Escher, Felicitas
A1  - Vogl, Thomas J.
A1  - Zeiher, Andreas M.
A1  - Nagel, Eike
A1  - Puntmann, Valentina O.
T1  - Myocardial fibrosis and inflammation by CMR predict cardiovascular outcome in people living with HIV
T2  - JACC Cardiovascular Imaging
N2  - Objectives_: The goal of this study was to examine prognostic relationships between cardiac imaging measures and cardiovascular outcome in people living with human immunodeficiency virus (HIV) (PLWH) on highly active antiretroviral therapy (HAART).
Background: PLWH have a higher prevalence of cardiovascular disease and heart failure (HF) compared with the noninfected population. The pathophysiological drivers of myocardial dysfunction and worse cardiovascular outcome in HIV remain poorly understood.
Methods: This prospective observational longitudinal study included consecutive PLWH on long-term HAART undergoing cardiac magnetic resonance (CMR) examination for assessment of myocardial volumes and function, T1 and T2 mapping, perfusion, and scar. Time-to-event analysis was performed from the index CMR examination to the first single event per patient. The primary endpoint was an adjudicated adverse cardiovascular event (cardiovascular mortality, nonfatal acute coronary syndrome, an appropriate device discharge, or a documented HF hospitalization).
Results: A total of 156 participants (62% male; age [median, interquartile range]: 50 years [42 to 57 years]) were included. During a median follow-up of 13 months (9 to 19 months), 24 events were observed (4 HF deaths, 1 sudden cardiac death, 2 nonfatal acute myocardial infarction, 1 appropriate device discharge, and 16 HF hospitalizations). Patients with events had higher native T1 (median [interquartile range]: 1,149 ms [1,115 to 1,163 ms] vs. 1,110 ms [1,075 to 1,138 ms]); native T2 (40 ms [38 to 41 ms] vs. 37 ms [36 to 39 ms]); left ventricular (LV) mass index (65 g/m2 [49 to 77 g/m2] vs. 57 g/m2 [49 to 64 g/m2]), and N-terminal pro–B-type natriuretic peptide (109 pg/l [25 to 337 pg/l] vs. 48 pg/l [23 to 82 pg/l]) (all p < 0.05). In multivariable analyses, native T1 was independently predictive of adverse events (chi-square test, 15.9; p < 0.001; native T1 [10 ms] hazard ratio [95% confidence interval]: 1.20 [1.08 to 1.33]; p = 0.001), followed by a model that also included LV mass (chi-square test, 17.1; p < 0.001). Traditional cardiovascular risk scores were not predictive of the adverse events.
Conclusions: Our findings reveal important prognostic associations of diffuse myocardial fibrosis and LV remodeling in PLWH. These results may support development of personalized approaches to screening and early intervention to reduce the burden of HF in PLWH (International T1 Multicenter Outcome Study; NCT03749343).
KW  - cardiac magnetic resonance
KW  - myocardial fibrosis
KW  - scar
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/71543
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-715436
SN  - 1876-7591
N1  - This study was supported by the German Ministry of Education and Research via the German Centre for Cardiovascular Research (DZHK) to Drs. Puntmann, Zeiher, and Nagel.
VL  - 14
IS  - 8
SP  - 1548
EP  - 1557
PB  - Elsevier
CY  - Amsterdam
ER  -